Created in 2007 by joint co-founders Gary Beale and Eamon McErlean, Emblation designs, manufactures and commercialises microwave-based solutions for a range of skin conditions. The technology, SWIFT, offers a non-ablative treatment for common and plantar warts.

Emblation’s products are also used in the treatment of certain cancers. Emblation’s systems are currently sold in the UK, North America and Australia, and have been used in over 130,000 treatments to date. Emblation’s medical devices can be found in thousands of clinics and hospitals across the UK, North America, and Australia, and the company is headquartered in Alloa.

Mr Beale, CEO, said: “We are pleased to have secured an investment from Apposite Capital which will allow us to accelerate our international expansion into new and existing markets as well as continue to build on our technology platform and deliver ground-breaking clinical results.

“Apposite immediately recognised the growth potential of our technology, and I am particularly excited to be working with the firm given their understanding of the sector and their expertise in scaling-up businesses like ours.”

He added: “Macdonald Henderson played an integral role throughout this transaction, and we benefited greatly from the experience and guidance of David Beveridge, Laura McKnight and their team.”